Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer

BACKGROUND: Bevacizumab and the antimetabolites capecitabine and gemcitabine have been shown to improve outcomes when added to taxanes in patients with metastatic breast cancer. The primary aims of this trial were to determine whether the addition of capecitabine or gemcitabine to neoadjuvant chemot...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Bear, Harry D., Tang, Gong, Rastogi, Priya, Geyer, Charles E., Robidoux, André, Atkins, James N., Baez-Diaz, Luis, Brufsky, Adam M., Mehta, Rita S., Fehrenbacher, Louis, Young, James A., Senecal, Francis M., Gaur, Rakesh, Margolese, Richard G., Adams, Paul T., Gross, Howard M., Costantino, Joseph P., Swain, Sandra M., Mamounas, Eleftherios P., Wolmark, Norman
Format: Artigo
Langue:Inglês
Publié: 2012
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3401076/
https://ncbi.nlm.nih.gov/pubmed/22276821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1111097
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires